Show simple item record

dc.contributor.authorJONG, Simcha
dc.date.accessioned2007-01-11T09:53:45Z
dc.date.available2007-01-11T09:53:45Z
dc.date.issued2006
dc.identifier.issn1725-6755
dc.identifier.urihttp://hdl.handle.net/1814/6433
dc.description.abstractDefying institutional stereotypes which state that the German capitalist model does not support the formation of entrepreneurial high tech industries in technologically disruptive markets, Munich entrepreneurs have succeeded in building up a significant biotech industry since the late 1990s. Using recruitment, citation and financial data this paper contrasts the development of therapeutic biotech firms founded after 1993 in Munich and Cambridge and analyzes how despite their comparative institutional disadvantages, Munich’s biotech firms have been able to develop the capabilities required to deal with a biotech firm’s key organizational challenges. This paper’s findings shed valuable insights on the mechanisms through which entrepreneurs in new industries are able defy national institutional settings that could constrain the development of key organizational capabilities and find alternative institutional paths to sustain the development of their firms.en
dc.format.extent152896 bytes
dc.format.mimetypeapplication/pdf
dc.language.isoenen
dc.relation.ispartofseriesEUI SPSen
dc.relation.ispartofseries2006/10en
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleThe Development of Minich and Cambridge Therapeutic Biotech Firms: A Case Study of Institutional Adaptationen
dc.typeWorking Paperen
eui.subscribe.skiptrue


Files associated with this item

Icon

This item appears in the following Collection(s)

Show simple item record